We understand the challenges emerging biotech companies face in the quest to push the next generation of drugs to market. This is why we have developed our EB Grant programs that we run on regular basis in different regions of the world. These programs allow grant recipients receive free products and services.
Recipients received between €25,000 and €100,000 in technologies and services to accelerate therapeutics to market. View Press Release.
Each grant recipient received 280,000 CNY in technologies and services.
NGM was awarded $89K in products and services. View Announcement.
If you want to be contacted regarding our next Emerging Biotech Grant Program, please leave your details and we will contact you.
Lack of funding is one of the main reasons for failure of a biologic.
Estimates vary, but some project it costs $8-10 million just to get to IND stage, another $8-10 million for Phase I, and $20-40 million for Phase II, depending on design. Phase III costs considerably more.
Don’t let a good drug go to waste, or too much of its value to third parties, because of funding issues. There are ways to fund biotech, from biotech crowdfunding, nondilutive funding, and nonsoursive funding, to biotech grants, angel investors, venture capital and other resources.
Intellectual property strategy is essential to protecting ideas and the business. Emerging biotech community members shared their insights.
Stay the Course
On the journey to commercialization, be sure to stay the course by understanding the global pharmaceutical regulatory landscape.
Bringing your molecule to market. As part of our commitment to meet the needs of the life science community, we’ve developed several programs that recognize stand-out emerging biotech companies. These programs are designed to support biotech start-ups and medium sized companies in solving their current bioprocess development challenges to bring the next generation of molecules to market.
Learn more about the ABCs of venture capital including how it works and the role of a corporate venture capital.
Learn more about the advantages to work with one source on your mAb, linker/ payload supplies and conjugation services.
Review the current dynamics in the RNA therapeutics/vaccines market with a focus on process development and manufacturing strategies.
Learn more on points to consider for successful tech transfers with a focus on cGMP training requirements.
Establishing an open dialog within the biotech community....
A report from the The Economist Intelligence Unit sponsored by Merck.
This paper, which incorporates the results of a survey of 254 pharmaceutical executives from around the world and a range of interviews with industry experts, explores in detail global pharmaceutical companies' growth strategies and their plans for managing the associated risks.